Inheritance in erythropoietic protoporphyria: a common wild-type ferrochelatase allelic variant with low expression accounts for clinical manifestation
- PMID: 10068685
Inheritance in erythropoietic protoporphyria: a common wild-type ferrochelatase allelic variant with low expression accounts for clinical manifestation
Abstract
Erythropoietic protoporphyria (EPP) is a rare autosomal dominant disorder of heme biosynthesis characterized by partial decrease in ferrochelatase (FECH; EC 4.99.1.1) activity with protoporphyrin overproduction and consequent painful skin photosensitivity and rarely liver disease. EPP is normally inherited in an autosomal dominant pattern with low clinical penetrance; the many different mutations that have been identified are restricted to one FECH allele, with the other one being free of any mutations. However, clinical manifestations of dominant EPP cannot be simply a matter of FECH haploinsufficiency, because patients have enzyme levels that are lower than the expected 50%. From RNA analysis in one family with dominant EPP, we recently suggested that clinical expression required coinheritance of a normal FECH allele with low expression and a mutant FECH allele. We now show that (1) coinheritance of a FECH gene defect and a wild-type low-expressed allele is generally involved in the clinical expression of EPP; (2) the low-expressed allelic variant was strongly associated with a partial 5' haplotype [-251G IVS1-23T IVS2microsatA9] that may be ancestral and was present in an estimated 10% of a control group of Caucasian origin; and (3) haplotyping allows the absolute risk of developing the disease to be predicted for those inheriting FECH EPP mutations. EPP may thus be considered as an inherited disorder that does not strictly follow recessive or dominant rules. It may represent a model for phenotype modulation by mild variation in expression of the wild-type allele in autosomal dominant diseases.
Similar articles
-
Hypermethylation of the wild-type ferrochelatase allele is closely associated with severe liver complication in a family with erythropoietic protoporphyria.Biochem Biophys Res Commun. 2004 Sep 3;321(4):851-8. doi: 10.1016/j.bbrc.2004.06.178. Biochem Biophys Res Commun. 2004. PMID: 15358105
-
Systematic analysis of molecular defects in the ferrochelatase gene from patients with erythropoietic protoporphyria.Am J Hum Genet. 1998 Jun;62(6):1341-52. doi: 10.1086/301870. Am J Hum Genet. 1998. PMID: 9585598 Free PMC article.
-
Modulation of penetrance by the wild-type allele in dominantly inherited erythropoietic protoporphyria and acute hepatic porphyrias.Hum Genet. 2004 Feb;114(3):256-62. doi: 10.1007/s00439-003-1059-5. Epub 2003 Dec 11. Hum Genet. 2004. PMID: 14669009
-
New insights into the pathogenesis of erythropoietic protoporphyria and their impact on patient care.Eur J Pediatr. 2000 Oct;159(10):719-25. doi: 10.1007/s004310000494. Eur J Pediatr. 2000. PMID: 11039124 Review.
-
[Inheritance in erythropoietic protoporphyria].Pathol Biol (Paris). 2010 Oct;58(5):372-80. doi: 10.1016/j.patbio.2010.01.007. Epub 2010 Sep 20. Pathol Biol (Paris). 2010. PMID: 20850938 Review. French.
Cited by
-
ACP Best Practice No 165: front line tests for the investigation of suspected porphyria.J Clin Pathol. 2001 Jul;54(7):500-7. doi: 10.1136/jcp.54.7.500. J Clin Pathol. 2001. PMID: 11429419 Free PMC article. Review.
-
The low expression allele (IVS3-48C) of the ferrochelatase gene leads to low enzyme activity associated with erythropoietic protoporphyria.Int J Hematol. 2010 Dec;92(5):769-71. doi: 10.1007/s12185-010-0725-3. Epub 2010 Dec 4. Int J Hematol. 2010. PMID: 21132468 No abstract available.
-
Delivery of oligonucleotides to bone marrow to modulate ferrochelatase splicing in a mouse model of erythropoietic protoporphyria.Nucleic Acids Res. 2020 May 21;48(9):4658-4671. doi: 10.1093/nar/gkaa229. Nucleic Acids Res. 2020. PMID: 32313951 Free PMC article.
-
Ferrochelatase: Mapping the Intersection of Iron and Porphyrin Metabolism in the Mitochondria.Front Cell Dev Biol. 2022 May 12;10:894591. doi: 10.3389/fcell.2022.894591. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35646904 Free PMC article. Review.
-
Protoporphyrin IX: the Good, the Bad, and the Ugly.J Pharmacol Exp Ther. 2016 Feb;356(2):267-75. doi: 10.1124/jpet.115.228130. Epub 2015 Nov 20. J Pharmacol Exp Ther. 2016. PMID: 26588930 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources